NASDAQ:PGEN Precigen Q2 2025 Earnings Results & Report $7.59 +0.11 (+1.52%) As of 09:58 AM Eastern This is a fair market value price provided by Massive. Learn more. Precigen beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.11 versus the -$0.14 consensus estimate, while revenue of $0.86 million topped the $0.67 million estimate by $0.19 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Precigen EPS ResultsActual EPS-$0.11Consensus EPS -$0.14Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersPrecigen Revenue ResultsActual Revenue$0.86 millionExpected Revenue$0.67 millionBeat/MissBeat by +$193.00 thousandYoY Revenue GrowthN/AUpcoming EarningsPrecigen's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Precigen Q2 2025 Earnings FAQ Did Precigen beat earnings estimates for Q2 2025? Precigen (NASDAQ:PGEN) reported earnings of -$0.11 per share for Q2 2025, beating the consensus estimate of -$0.14. The report was announced on Tuesday, August 12, 2025. What was Precigen's revenue for Q2 2025? Precigen reported revenue of $0.86 million for Q2 2025, against a consensus estimate of $0.67 million. When is Precigen's next earnings date? Precigen's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Precigen on the company's earnings history page. Precigen Earnings HeadlinesCritical Comparison: Precigen (NASDAQ:PGEN) vs. Pyxis Oncology (NASDAQ:PYXS)October 12 at 5:29 AM | americanbankingnews.comZacks Research Downgrades Precigen (NASDAQ:PGEN) to HoldOctober 7, 2026 | americanbankingnews.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 14 at 1:00 AM | Behind the Markets (Ad)Precigen (NASDAQ:PGEN) Stock Falls 6.5% - Here's WhyOctober 5, 2026 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) versus Precigen (NASDAQ:PGEN) Head to Head ContrastOctober 5, 2026 | americanbankingnews.comPGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?September 30, 2026 | finance.yahoo.comSee More Precigen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email. Email Address About PrecigenPrecigen (NASDAQ:PGEN) (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases, including cancer, infectious diseases and certain immune-related conditions. The company uses its proprietary technologies to engineer therapies intended to improve treatment precision, durability and accessibility. Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis, as well as programs based on its UltraCAR-T platform for cancer treatment. The company has also developed additional gene- and cell-therapy candidates using engineered viral vectors and other biologic delivery technologies. Precigen was formerly known as Intrexon Corporation and adopted its current name in 2020. The company is headquartered in Germantown, Maryland, and conducts its research and clinical-development activities primarily in the United States. Helen Sabzevari serves as Precigen’s president and chief executive officer.View Precigen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
